Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06080438 · ClinicalTrials.gov registry record · Phase 4
Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure
A Phase 4 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT06080438 is a Phase 4 study that was terminated before completion, run by University of Miami. The registered enrollment target is 2 participants.
The verdict
NCT06080438, a Phase 4 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this research study is to test if Topical (applied to the surface of the eye) Botulinum Toxin temporarily lowers the upper eyelid and makes the eyelid appear less open and thereby affects the eye surface and decreases reflexive tearing.
Interventions
- DRUG Botulinum toxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-11-29 |
| Est. Completion | 2024-07-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06080438
The ClinicalTrials.gov registry entry for NCT06080438 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin is the first listed.
NCT06080438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06080438 about?
NCT06080438 is a clinical study titled "Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure". The purpose of this research study is to test if Topical (applied to the surface of the eye) Botulinum Toxin temporarily lowers the upper eyelid and makes the eyelid appear less open and thereby affects the eye surface and decreases reflexive tearing.
What is the current status of trial NCT06080438?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2022-11-29. Estimated completion is 2024-07-28.
What interventions are being tested in trial NCT06080438?
The interventions under investigation include: Botulinum toxin (DRUG).
Who is sponsoring clinical trial NCT06080438?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.